Examples of using Repeat-dose toxicity in English and their translations into Romanian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
Genotoxicity and repeat-dose toxicity studies of one month
A repeat-dose toxicity study was conducted in juvenile rats 8 days post-partum for 4 weeks with aliskiren dosing at 30,
In a repeat-dose toxicity studies in rats
Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity conducted with immediate-release exenatide or prolonged-release exenatide.
Non-clinical safety data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction.
In repeat-dose toxicity studies, conducted in mice,
5 mg/kg in the 4-week repeat-dose toxicity study.
Repeat-dose toxicity studies performed in rats
In repeat-dose toxicity studies, conducted in mice,
Repeat-dose toxicity studies in rats,
fertility in humans based on findings in repeat-dose toxicity studies in the rat.
In rat and dog repeat-dose toxicity studies up to 3-month duration,
No adverse effects on male and female reproductive organs were observed in repeat-dose toxicity studies in cynomolgus monkeys(see section 5.3).
A slightly increased incidence of thickening of the atrioventricular valves of the heart was seen in the 26 week repeat-dose toxicity study in rats.
Abnormal respiration, heart rate changes and decreased activity were observed soon after intravenous injection of Luminity at doses 0.3 ml/kg in single and repeat-dose toxicity studies in rats and monkeys.
Abnormal respiration, heart rate changes and decreased activity were observed soon after intravenous injection of Luminity at doses≥ 0.3 ml/ kg in single and repeat-dose toxicity studies in rats and monkeys.
Non-clinical safety data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, and genotoxicity, except for changes to reproductive tissues related to the extended pharmacology of loxapine. Similar changes, e.g.
Repeat-dose toxicity studies have shown that levels up to 200 mg/kg/day are well tolerated in rats;
However, in single and repeat-dose general toxicity studies no adverse reactions at the injection sites were reported.
In repeat-dose toxicity studies in cynomolgus monkeys obinutuzumab had no adverse effects on male